Search filters

Filters

Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 118
  • 387
  • 180
  • 13
  • 19
  • 355
  • 382
  • 5
  • 4
  • 383

Found 387 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

12 years - 99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

All genders
Phase 1/2
Interventional
The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat …

UPCC 44419: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

18 years - 99 years
All genders
Phase 2
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and …

Evaluation of Enhanced Gastrointestinal Cancer Screening in Lymphoma Survivors Treated with Prior Radiation Therapy

All genders
Lymphoma survivors who were treated with prior radiation therapy have been shown to have an increased risk of cancers of the gastrointestinal system. This increased cancer risk may be due to damage to cells in your gastrointestinal system that is caused at the time of radiation. This research is being …

UPCC 17518: A Phase 1 First-in-Human Open-Label Dose Escalation Study of MGD013 A Bispecific DART Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

All genders
Phase 1
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
 The Cancer of the Pancreas Screening-5

The Cancer of the Pancreas Screening-5

1 years - 99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
 Physiologic MR Imaging in Distinguishing Benign from Malignant Salivary Gland Tumors

Physiologic MR Imaging in Distinguishing Benign from Malignant Salivary Gland Tumors

18 years - 99 years
All genders
The purpose of this research study is to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and also aid in the prediction of disease progression. It is important to determine whether the salivary gland tumor is cancerous prior to operation because this information …
 Whole-Brain Spectroscopy Guided Personalized Delivery of Tumor Treating Fields in Glioblastoma Patients

Whole-Brain Spectroscopy Guided Personalized Delivery of Tumor Treating Fields in Glioblastoma Patients

22 years - 99 years
All genders
The research study is for Glioblastoma (GBM) patients beginning Optune, a therapy that uses - tumor treating fields (TTFields). As a part of this study participants will either receive Optune with standard treatment array mapping from MR imaging or an alternative treatment array mapping based on advanced MR imaging also …
211 - 220 of 387